Company: ABBV
Filing Date: 2025-02-14
Form Type: S-3ASR
Source: 0001104659-25-014191
Chunk: 1

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: S-3ASR
Chunk 1
---
� If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒ If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| ​ | Large accelerated filer 
 ☒                       
 ​                       | ​ | ​ | Accelerated filer         
 ☐                         
 ​                         | ​ |
| ​ | Non-accelerated filer   
 ☐                       
 ​                       | ​ | ​ | Smaller reporting company 
 ☐                         
 ​                         | ​ |
| ​ | ​                       | ​ | ​ | Emerging growth company   
 ☐                         
 ​                         | ​ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

TABLE OF CONTENTS

### PROSPECTUS

#### ABBVIE INC.

#### Debt Securities
This prospectus relates to the sale of one or more series of debt securities of AbbVie Inc., a Delaware corporation (“AbbVie,” “we,” “us” or the “Company”), from time to time, on terms and at prices determined at the time the debt securities are offered for sale. The terms and prices will be described in more detail in one or more supplements to this prospectus. Before investing, you should carefully read this prospectus and any related prospectus supplement or free writing prospectus. Prospectus supplements or free writing prospectuses may also add, update, or change information contained in this prospectus.

We may offer and sell these securities to or through agents, underwriters, dealers, or directly to purchasers on a continuous or a delayed basis. The names of any agents, underwriters, or dealers and the